[
  {
    "ts": null,
    "headline": "Barclays Initiates Coverage of Merck (MRK) with Overweight Recommendation",
    "summary": "Barclays Initiates Coverage of Merck (MRK) with Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=caf01aa82372ec24903dfe10b771a97ceb76183b27954698a79061f71f06fe8c",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771617855,
      "headline": "Barclays Initiates Coverage of Merck (MRK) with Overweight Recommendation",
      "id": 139163481,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=caf01aa82372ec24903dfe10b771a97ceb76183b27954698a79061f71f06fe8c"
    }
  },
  {
    "ts": null,
    "headline": "Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?",
    "summary": "BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.",
    "url": "https://finnhub.io/api/news?id=8fb0c318dd7273d4f986ab8f76fe50cdc438d4411227f1d342dc9689d425befe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771607100,
      "headline": "Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?",
      "id": 139163218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.",
      "url": "https://finnhub.io/api/news?id=8fb0c318dd7273d4f986ab8f76fe50cdc438d4411227f1d342dc9689d425befe"
    }
  },
  {
    "ts": null,
    "headline": "Time To Take Profits On Gilead Sciences (Rating Downgrade)",
    "summary": "Time To Take Profits On Gilead Sciences (Rating Downgrade)",
    "url": "https://finnhub.io/api/news?id=76403649db781f3cc035644fc3334ab00c2581eb4eb76ed5397cb9c671441e6e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771597457,
      "headline": "Time To Take Profits On Gilead Sciences (Rating Downgrade)",
      "id": 139163044,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=76403649db781f3cc035644fc3334ab00c2581eb4eb76ed5397cb9c671441e6e"
    }
  },
  {
    "ts": null,
    "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
    "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
    "url": "https://finnhub.io/api/news?id=24defe4374fd77db8c0683e041cc1dc376df6732125794a437ba7de5060bb531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771592903,
      "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
      "id": 139159098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
      "url": "https://finnhub.io/api/news?id=24defe4374fd77db8c0683e041cc1dc376df6732125794a437ba7de5060bb531"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
    "summary": "Pre-Market Stock Futures: Futures are trading lower as we wrap up the holiday-shortened week that gave us a little taste of just about everything. While Walmart posted results that beat expectations, its forward guidance and outlook fell short of Wall Street’s expectations, and the stock was down from the opening bell to the close. All ... Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
    "url": "https://finnhub.io/api/news?id=b83b4e394a5218c16e943180ffaeba77995521445b0579bf447ccffd97229ce7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771592369,
      "headline": "Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
      "id": 139159483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: Futures are trading lower as we wrap up the holiday-shortened week that gave us a little taste of just about everything. While Walmart posted results that beat expectations, its forward guidance and outlook fell short of Wall Street’s expectations, and the stock was down from the opening bell to the close. All ... Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
      "url": "https://finnhub.io/api/news?id=b83b4e394a5218c16e943180ffaeba77995521445b0579bf447ccffd97229ce7"
    }
  },
  {
    "ts": null,
    "headline": "No one-trick pony in oncology, Merck’s cancer footprint is expanding",
    "summary": "The three key therapeutic approaches Merck is leveraging to craft its next era in cancer care.",
    "url": "https://finnhub.io/api/news?id=416985875b154b1ed57d03be26bd52a39d546b290621831968412c83ac828b5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771574400,
      "headline": "No one-trick pony in oncology, Merck’s cancer footprint is expanding",
      "id": 139159137,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The three key therapeutic approaches Merck is leveraging to craft its next era in cancer care.",
      "url": "https://finnhub.io/api/news?id=416985875b154b1ed57d03be26bd52a39d546b290621831968412c83ac828b5f"
    }
  }
]